2026-04-04 · Consumer-facing clinical trial results intelligence — auto-collecting newly completed trial results from ClinicalTrials.gov, translating them into plain-English verdict articles with data visualizations, scorecards, and honest "should you care?" assessments.

Trial Verdict

Every week, science finishes an experiment on your health. We read the results so you don't have to.

💡 idea Total 16/20 Quality 5 Automation 4 Revenue 3 Complexity 4

Channel: Trial Verdict Tagline: Every week, science finishes an experiment on your health. We read the results so you don’t have to. Niche: Consumer-facing clinical trial results intelligence — auto-collecting newly completed trial results from ClinicalTrials.gov, translating them into plain-English verdict articles with data visualizations, scorecards, and honest “should you care?” assessments. Target audience: Health-conscious adults (25-65) with chronic conditions or family members with them; people who Google “[drug name] clinical trial results” after seeing a news headline; patient advocates; the “I want to understand my options” crowd — estimated 130M+ Americans with chronic conditions, plus global English-speaking audience. Why now: Three converging forces:

The GLP-1/weight loss drug explosion has made clinical trial literacy mainstream — millions of people now actively follow trial results for semaglutide, tirzepatide, orforglipron
EU Clinical Trials Regulation now mandates plain language summaries, creating a new awareness that trial results should be understandable
ClinicalTrials.gov v2 API launched in 2024 — a dramatically better programmatic interface that returns rich structured JSON, making automated analysis finally practical

Content Example

Sample headline:

“Orforglipron vs. Oral Semaglutide: The Head-to-Head Weight Loss Trial — A Clear Winner Emerges”

Sample article excerpt:

Trial Verdict Score: ⚖️ STRONG EVIDENCE

The Bottom Line: Eli Lilly’s oral GLP-1 pill orforglipron beat Novo Nordisk’s oral semaglutide on weight loss by a significant margin in a direct comparison trial involving 1,362 participants with obesity. After 40 weeks, the high-dose orforglipron group lost 12.6% of body weight versus 8.2% for oral semaglutide. If confirmed in phase 3, this could mean a second-generation weight loss pill that’s meaningfully more effective.

Why You Should Care: If you’ve been following the GLP-1 revolution, you know that pills lag behind injections in effectiveness. This trial suggests orforglipron might close that gap — potentially eliminating the needle entirely for many patients. It also signals a real competitive race that could drive prices down.

The Numbers That Matter:

Measure	Orforglipron 36mg	Oral Semaglutide 50mg	Placebo
Body weight change	-12.6%	-8.2%	-2.1%
≥5% weight loss achieved	79%	61%	28%
≥10% weight loss achieved	54%	34%	8%
Discontinued due to adverse events	11%	9%	3%

[Auto-generated bar chart visualization would appear here showing comparative weight loss]

The Honesty Corner — Side Effects: Both drugs cause the familiar GI issues — nausea hit 33% of orforglipron users vs 26% on semaglutide. Vomiting was higher with orforglipron (16% vs 10%). The dropout rate for side effects was slightly higher with orforglipron. Translation: it works better, but the stomach complaints are also slightly worse.

What This Trial CAN’T Tell You:

Long-term safety beyond 40 weeks (we don’t know yet)
Whether the weight stays off after stopping (not measured)
Cost comparison (orforglipron isn’t approved yet)
How it compares to injectable semaglutide or tirzepatide

Trial Card:

📋 NCT ID: NCT06490341
👥 Participants: 1,362 adults with BMI ≥30 (or ≥27 with comorbidity)
⏱️ Duration: 40 weeks
🏥 Sponsor: Eli Lilly
📊 Design: Randomized, double-blind, active-comparator
🔬 Phase: 2
🌍 Sites: 145 sites across 12 countries

Methodology note: Phase 2 trials are smaller and designed to find optimal dosing. The dropout rate of ~15% is within normal range but worth watching. Results were statistically significant (p<0.001 for primary endpoint).

Data Sources

ClinicalTrials.gov v2 API — Primary. Query https://clinicaltrials.gov/api/v2/studies with filter.advanced=AREA[ResultsFirstPostDate]RANGE[{7_days_ago},{today}] to find trials that posted results in the past week. Returns full structured outcome measures, adverse events, participant demographics. FREE, no API key. JSON responses.
PubMed/NCBI E-utilities API — Secondary. Cross-reference NCT numbers to find linked publications with abstracts for deeper AI analysis context. https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term={NCT_ID}. FREE with optional API key for higher rate limits.
OpenFDA Drug Adverse Events API — Enrichment. Pull real-world adverse event data for drugs mentioned in trial results. https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:{drug}. FREE, no key.
WHO GHO OData API — Context. Disease burden data (prevalence, mortality) to contextualize why a trial matters. https://ghoapi.azureedge.net/api/{indicator_code}. FREE.
Europe PMC REST API — Supplementary. Open access full-text articles for additional context. https://www.ebi.ac.uk/europepmc/webservices/rest/search?query={NCT_ID}. FREE.

Automation Pipeline

Schedule: GitHub Actions cron — twice weekly (Monday and Thursday, 08:00 UTC)
Collect:
1. Query ClinicalTrials.gov v2 API for trials with ResultsFirstPostDate in last 3-4 days
2. Filter to Phase 2/3/4 trials with ≥100 participants (skip tiny pilot studies)
3. Score trials by public interest: condition prevalence × intervention novelty × sponsor visibility
4. Select top 5-8 most interesting trials per run
5. For each: pull linked PubMed abstracts, OpenFDA adverse event context, WHO disease burden
Process:
1. AI synthesizes structured trial data into plain-language verdict article
2. Assigns Trial Verdict Score (Preliminary Evidence → Moderate Evidence → Strong Evidence → Practice-Changing)
3. Generates “Honesty Corner” — what the trial CAN’T tell you (limitations analysis)
4. Creates “Why You Should Care” contextualization using disease burden data
5. Fact-checks claims against primary outcome measures (automated verification)
Generate:
1. Outcome comparison bar/line charts from numerical results data (D3.js / Chart.js rendered to SVG/PNG)
2. Trial Scorecard infographic (participant count, duration, phase, design type)
3. Adverse event frequency radar charts
4. Condition prevalence context maps (if geographic data available)
5. Article hero images via AI image generation (condition-themed, branded style)
Publish: Build static site → deploy to GitHub Pages / Cloudflare Pages

Tech Stack

Static site: TypeScript + Astro (content-heavy, excellent SEO, island architecture for interactive charts)
Image generation: Chart.js / D3.js for data viz (server-rendered to PNG in GitHub Actions), DALL-E or Stable Diffusion for article hero images
Data collection: TypeScript scripts using fetch() against REST APIs — no scraping, all structured API data
AI analysis: OpenAI GPT-4o / Claude for article generation with structured prompts and fact-checking guardrails
CI/CD: GitHub Actions (twice-weekly cron + manual dispatch)
Hosting: Cloudflare Pages (free tier, fast global CDN, excellent for static sites)
Search: Pagefind (client-side search, zero-cost)
Newsletter: Buttondown or Listmonk (self-hosted) for email digest

Monetization Model

Channel 1: Donations/Tips — Buy Me a Coffee, GitHub Sponsors, Ko-fi. Health content inspires gratitude (“this helped me understand my options”). Target: $200-500/month by month 3.
Channel 2: Newsletter Premium Tier — Free weekly digest + premium “Deep Dive” for specific conditions (diabetes trials only, cancer trials only). $5/month. Target: 200 premium subs by month 6 = $1,000/month.
Channel 3: Affiliate — Health-adjacent affiliate: continuous glucose monitors, home health testing kits (LetsGetChecked, Everlywell), health tracking apps. Genuinely relevant to audience. Target: $300-800/month by month 6.
Channel 4: Sponsored — Pharma companies and health tech startups would sponsor condition-specific sections. Patient advocacy orgs would sponsor for visibility. Target: $500-2,000/month by month 6+.
Channel 5: Telegram with Stars — Weekly trial verdict highlights. Engaged health community.
Projected month-1 revenue: $50-150 (donations from early sharers)
Projected month-6 revenue: $2,000-4,500 (newsletter premium + affiliate + early sponsorship)

The Soul of Trial Verdict

Name: Trial Verdict — authoritative, clear, implies judgment and clarity
Mascot: “Doc Clarity” — an illustrated owl wearing a lab coat and half-moon reading glasses, always looking slightly skeptical. Appears in article headers giving a 👍 or 🤔 or ⚠️ depending on evidence strength. Owl = wisdom, lab coat = science, glasses = reading the fine print.
Voice: The smart friend who went to med school but talks like a normal person. Slightly irreverent. Not afraid to say “this trial was underpowered and you shouldn’t get excited yet.” Uses analogies (“Think of it like A/B testing, but for your liver”). Explains statistics without dumbing down — treats readers as intelligent adults who just don’t have the jargon.
Opinion: Trial Verdict takes a stance. It rates evidence strength. It calls out poorly designed trials. It highlights when pharma sponsors might have conflicts of interest. It says “this is exciting” or “this is overhyped” — it doesn’t just report.
Running traditions:
- “The Verdict” — every article ends with a clear 1-sentence verdict
- “Honesty Corner” — what the trial CAN’T tell you (always present)
- “Week in Trials” — Monday recap ranking the week’s most interesting results
- “Hype Check” — monthly feature debunking viral health claims using actual trial data
- “The Long Game” — quarterly follow-ups on previously covered trials
Visual style: Clean, medical but warm. Navy blue + teal + white palette. Custom data visualizations are the hero — big, beautiful charts that make complex data immediately understandable. Monospace font for data callouts. Generous whitespace. Mobile-first card layout.
Tone example: “Pharma press releases will tell you this drug ‘achieved statistical significance on the primary endpoint.’ Trial Verdict will tell you that means 4% more people had slightly fewer headaches, but also 8% more people got nauseated. You decide if that’s a win.”

Scores

Launch Complexity: 3/5 — APIs are free and well-documented, structured data makes AI analysis reliable, but AI prompt engineering for medical accuracy needs careful tuning and a robust fact-checking layer Content Quality Score: 5/5 — This is the dream niche for quality automation: input data is structured, numerical, and verifiable. No “AI making stuff up” risk because every claim maps to a specific outcome measure with a specific number. The AI’s job is translation and contextualization, not fabrication. Automation Score: 4/5 — End-to-end automatable once prompts are tuned. Only manual step: occasional review of AI outputs for medical sensitivity (could be reduced with confidence scoring). The ClinicalTrials.gov API is remarkably well-structured. Revenue Potential: 5/5 — Health is the highest-value content niche. Health newsletter subscribers are worth $3-8 each. Pharma/health-tech sponsors pay premium CPMs. Affiliate commissions on health products are strong. And this content has genuine social value — people share things that help them understand their health.

Total: 17/20

Why This Will Work

Psychology: People are desperate for health information they can actually understand. When a trial result makes the news (“New Alzheimer’s drug shows promise!”), millions of people Google it and find… impenetrable medical journals, breathless press releases, or clickbait. Nobody is consistently translating the actual structured data from ClinicalTrials.gov into beautiful, honest, consumer-grade content. Trial Verdict fills this gap.

Market logic:

The data source is free, structured, and constantly updating (~100-200 new trial results/week)
Every article targets a long-tail keyword cluster with almost zero competition
Condition-specific audiences are incredibly engaged and willing to share/support
SEO compounds: every article is an evergreen reference for that trial, that drug, that condition
The EU mandate for plain language summaries is training consumers to expect this kind of content

Network effects: Each article attracts a condition-specific audience. Those people subscribe for their condition → see articles about adjacent conditions → share with their communities → flywheel.

Risk & Mitigation

Medical misinformation risk: Highest concern. Mitigation: every claim must map to specific structured data fields from ClinicalTrials.gov. AI never invents statistics. Prominent disclaimers. “This is not medical advice” on every page. Consider medical advisor review for the first 50 articles.
API reliability: ClinicalTrials.gov API is a US government service — generally reliable but can have downtime. Mitigation: cache responses, implement retry logic, have a 24h grace period for collection.
AI hallucination: The structured nature of the input data heavily mitigates this — numbers come directly from the API, not AI imagination. Implement automated verification: cross-check AI-written statistics against source data.
Legal/regulatory: Must be extremely careful with health claims. Mitigation: position as “journalism about science” not “health advice.” No treatment recommendations. Clear disclosures.
Content volume bottleneck: 100+ trials/week means curation is critical. Mitigation: automated scoring algorithm ranks trials by public interest (condition prevalence × novelty × sample size) to select the best 10-15 per week.